TTLL3: Potential Cancer and Tissue Engineering Target (G26140)

Target Name: TTLL3

NCBI ID: G26140

TTLL3

TTLL3: Potential Cancer and Tissue Engineering Target

TTLL3 (Tumor suppressor gene-containing gene 3) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The gene is located on chromosome 17 and has been shown to play a role in the development and progression of various types of cancer.

TTLL3 is a tumor suppressor gene that encodes a protein known as TTLL3-containing gene 3 (TTLG3). The TTLG3 protein is a negative regulator of the tumor suppressor gene PIK3CA, which is a well-known gene that is involved in the regulation of cell growth and survival. PIK3CA has been implicated in the development of many types of cancer, including breast, ovarian, and colorectal cancer.

TTLL3 has been shown to play a role in the regulation of PIK3CA function. Studies have shown that TTLL3 can inhibit the activity of PIK3CA and that this inhibition can lead to the growth and survival of cancer cells. This suggests that TTLL3 may be a useful target for cancer treatment.

In addition to its role in cancer development, TTLL3 has also been shown to be involved in the regulation of stem cell maintenance. stem cells are a type of cell that have the ability to develop into any type of cell in the body, and they play a critical role in the development and maintenance of tissues and organs.

Studies have shown that TTLL3 can induce the stem cell-to-progenitor cell transition, a process that is critical for the development of tissues and organs. This suggests that TTLL3 may be a useful target for tissue engineering and regenerative medicine.

TTLL3 has also been shown to play a role in the regulation of inflammation. inflammation is a critical immune response that helps to protect the body against infection and disease, but it can also contribute to the development of many types of chronic diseases, including cancer.

Studies have shown that TTLL3 can regulate the production of pro-inflammatory cytokines, which are important drivers of inflammation. This suggests that TTLL3 may be a useful target for the treatment of inflammatory diseases, including cancer.

In conclusion, TTLL3 is a gene that has been shown to play a role in the regulation of tumor suppressor gene function, stem cell maintenance, and inflammation. These findings suggest that TTLL3 may be a useful drug target or biomarker for the treatment of various types of cancer and other diseases. Further research is needed to fully understand the role of TTLL3 in these processes and to develop effective treatments.

Protein Name: Tubulin Tyrosine Ligase Like 3

Functions: Monoglycylase which modifies alpha- and beta-tubulin, adding a single glycine on the gamma-carboxyl groups of specific glutamate residues to generate monoglycine side chains within the C-terminal tail of tubulin. Not involved in elongation step of the polyglycylation reaction (By similarity). Preferentially glycylates a beta-tail peptide over the alpha-tail, although shifts its preference toward alpha-tail as beta-tail glutamylation increases (By similarity). Competes with polyglutamylases for modification site on beta-tubulin substrate, thereby creating an anticorrelation between glycylation and glutamylation reactions (By similarity). Together with TTLL8, mediates microtubule glycylation of primary and motile cilia, which is essential for their stability and maintenance (By similarity). Involved in microtubule glycylation of primary cilia in colon which controls cell proliferation of epithelial cells and plays an essential role in colon cancer development (PubMed:25180231). Together with TTLL8, glycylates sperm flagella which regulates axonemal dynein motor activity, thereby controlling flagellar beat, directional sperm swimming and male fertility (By similarity)

The "TTLL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets